Stressed Out: RNA-binding Protein Inhabits Granules in ALS, FTD
Meet RBM45. This RNA-binding protein and relatively new player in the ALS field associates with stress-induced structures in the cytoplasm and nucleus.
ALL NEWS
6545 RESULTS
Sort By:
- Most Recent
- Most Commented
Unexpected Polypeptides Pop Up in Huntington’s Disease
In a process known as repeat-associated non-ATG translation, neurons and glia make alanine, serine, cysteine, and leucine chains from the huntingtin gene.
Gantenerumab, Aducanumab: Bobbing Up and Down While Navigating Currents of Trial Design
Both antibodies might be working, experts say, but the latest data released at the CTAD conference remain tantalizingly unclear. Trialists urgently need progression predictors and better outcome measures.
Clinical Trials on Alzheimer’s Disease 2015
Gantenerumab, Aducanumab: Bobbing Up and Down While Navigating Currents of Trial Design Outcomes, Outcomes: Cognition is Crux of New Alzheimer’s Trials Truly New to Déjà Vu: Investigational Therapy News at CTAD Truly New to Déjà Vu: For Five Hopefuls, Lig
Outcomes, Outcomes: Cognition is Crux of New Alzheimer’s Trials
The CTAD conference featured discussion among many scientists of how to measure a drug’s effect in pre-dementia patients who are so mildly impaired that established tools have trouble picking up improvement. Better cognitive tools are needed.
Truly New to Déjà Vu: Investigational Therapy News at CTAD
Several therapeutic approaches in Phase 3 reported updates at the CTAD conference earlier this month in Barcelona. Read about levetiracetam, deep brain stimulation, and scyllo-inositol.
Truly New to Déjà Vu: For Five Hopefuls, Lights Go Out After Phase 2
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
Truly New to Déjà Vu: Phase 1 Means ‘Check!’ for Some, ‘Out!’ for Others
At CTAD, investigational Phase 1 drugs include a repackaged and a new anti-amyloid, a tau vaccine, and a repurposed cancer drug.
Health Interventions Boost Cognition—But Do They Delay Dementia?
The leaders of two large European trials report that promoting cardiac health, exercise, and mental activity helped maintained cognition in older adults.
Can Common Genetic Variation in Mice Nail Genes of Aging, Alzheimer’s?
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
Preclinical Research Offers New Angles on Immunotherapy
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
C9ORF72 Mice A-OK Despite Toxic RNAs, Peptides
Mouse lines made by two different labs replicate the molecular pathology, but not the neurodegeneration, of ALS and FTD based on C9ORF72 expansions.
Breast Cancer Gene Implicated in Alzheimer’s
The BRCA1 protein protects neurons from DNA damage, but levels tumble in Alzheimer’s disease.
Biomarker Study in Down’s Syndrome Population May Yield Clues to AD
NIH announced a five-year study of Alzheimer’s biomarkers in middle-aged people with Down’s syndrome.
Gene and Stem Cell Therapies Make Strong Showing at ALS/MND Meeting
Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
Current Filters
No filters selected